Publications by authors named "V LIPKOVA"
Article Synopsis
- The study aimed to assess the effectiveness of pegcetacoplan, a drug designed to inhibit certain proteins, on slowing the progression of geographic atrophy (GA) in patients using advanced imaging techniques.
- Analyzing data from the FILLY phase 2 trial, the study examined 288 eyes from 144 patients with bilateral GA, comparing treated eyes to untreated fellow eyes after 12 months of treatment with either pegcetacoplan or sham injections.
- Results indicated that pegcetacoplan treatment led to significantly reduced annual growth of GA in various metrics compared to untreated eyes, while the sham treatment showed no impact, although results from another treatment schedule showed non-significant trends.
Importance: Diabetic macular edema (DME) is a major cause of vision loss in patients with diabetes mellitus. Intravitreal dexamethasone is a treatment option for patients unsuitable for or non-responsive to anti-angiogenic agents.
Objective: To quantify visual and anatomical outcomes from an initial intravitreal dexamethasone injection over the expected 6-month period of dexamethasone release by the implant.
Objective: To evaluate the role of automated optical coherence tomography (OCT) segmentation, using a validated deep-learning model, for assessing the effect of C3 inhibition on the area of geographic atrophy (GA); the constituent features of GA on OCT (photoreceptor degeneration (PRD), retinal pigment epithelium (RPE) loss and hypertransmission); and the area of unaffected healthy macula.To identify OCT predictive biomarkers for GA growth.
Methods: Post hoc analysis of the FILLY trial using a deep-learning model for spectral domain OCT (SD-OCT) autosegmentation.